Key Takeaways:
IDEAYA Biosciences Inc. (Nasdaq: IDYA) will present complete data from its Phase 2/3 registrational trial of darovasertib and crizotinib for metastatic uveal melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
The late-breaking abstract was selected for an oral presentation at the conference, which takes place from May 29 to June 2 in Chicago. "The selection for a late-breaking oral presentation at ASCO underscores the potential significance of the data from our registrational trial," a company spokesperson said.
The OptimUM-02 trial evaluates the combination of darovasertib, a PKC inhibitor, with crizotinib, a c-MET inhibitor, in patients with first-line HLA*A2-negative metastatic uveal melanoma (MUM). Key efficacy data, including response rates and progression-free survival, are not yet disclosed but will be the focus of the ASCO presentation. Safety data, including the rate of adverse events, will also be presented.
The presentation comes as the oncology community gathers for several key data readouts. ImPact Biotech is also scheduled to present updated data for its Padeliporfin VTP therapy in different solid tumors at the same conference, highlighting a busy season for oncology investors. For IDEAYA, positive data could pave the way for a New Drug Application (NDA) filing with the U.S. Food and Drug Administration.
A successful outcome in the Phase 2/3 trial would be a major catalyst for IDEAYA, as metastatic uveal melanoma has limited treatment options. Investors will be closely watching the ASCO presentation on June 1 for the full data set, which will determine the drug combination's viability as a potential new standard of care.
This article is for informational purposes only and does not constitute investment advice.
